An ascending multiple-dose study of the safety, pharmacokinetics, and pharmacodynamics of SLV-313 sustained-release (SR) tablets administered orally to subjects with schizophrenia and schizoaffective disorder.

Trial Profile

An ascending multiple-dose study of the safety, pharmacokinetics, and pharmacodynamics of SLV-313 sustained-release (SR) tablets administered orally to subjects with schizophrenia and schizoaffective disorder.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2010

At a glance

  • Drugs SLV 313 (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions
  • Sponsors Wyeth
  • Most Recent Events

    • 22 Jul 2009 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 22 Jul 2009 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 18 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top